Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:47 UTC |
---|
HMDB ID | HMDB0014911 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Etoposide |
---|
Description | Etoposide, also known as vepesid or VP-16, belongs to the class of organic compounds known as podophyllotoxins. These are tetralin lignans in which the benzene moiety of the tetralin skeleton is fused to a 1,3-dioxolane and the cyclohexane is fused to a butyrolactone (pyrrolidin-2-one). Etoposide is a drug. Within humans, etoposide participates in a number of enzymatic reactions. In particular, etoposide can be converted into etoposide ortho-quinone; which is mediated by the enzymes prostaglandin g/h synthase 1 and prostaglandin g/h synthase 2. In addition, etoposide and uridine diphosphate glucuronic acid can be converted into etoposide glucuronide and uridine 5'-diphosphate; which is mediated by the enzyme UDP-glucuronosyltransferase 1-1. In humans, etoposide is involved in etoposide metabolism pathway. Etoposide is formally rated as a carcinogen (by IARC 1) and is also a potentially toxic compound. Etoposide is used as a form of chemotherapy for cancers such as Kaposi's sarcoma, Ewing's sarcoma, lung cancer, testicular cancer, lymphoma, nonlymphocytic leukemia, and glioblastoma multiforme. It is given intravenously (IV) or orally in capsule or tablet form. It is believed to work by damaging DNA. Etoposide was approved for medical use in the United States in 1983. They can include low blood cell counts, vomiting, loss of appetite, diarrhea, hair loss, and fever. |
---|
Structure | [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(-)-Etoposide | ChEBI | 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) | ChEBI | 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside | ChEBI | 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one | ChEBI | Eposin | ChEBI | Etopophos | ChEBI | Etoposido | ChEBI | Etoposidum | ChEBI | Lastet | ChEBI | Toposar | ChEBI | trans-Etoposide | ChEBI | Vepesid | ChEBI | VP-16 | ChEBI | 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside) | Generator | 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside) | Generator | 4-Demethylepipodophyllotoxin b-D-ethylideneglucoside | Generator | 4-Demethylepipodophyllotoxin β-D-ethylideneglucoside | Generator | 9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one | Generator | 9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one | Generator | Baxter oncology brand OF etoposide | HMDB | Bristol myers brand OF etoposide | HMDB | Bristol-myers squibb brand OF etoposide | HMDB | Demethyl epipodophyllotoxin ethylidine glucoside | HMDB | Etomedac | HMDB | Etoposide teva | HMDB | Exitop | HMDB | Pierre fabre brand OF etoposide | HMDB | Bristol myers squibb brand OF etoposide | HMDB | Bristol-myers brand OF etoposide | HMDB | Celltop | HMDB | Etoposide pierre fabre | HMDB | Etoposide, (5a alpha)-isomer | HMDB | Etoposide, (5a alpha,9 alpha)-isomer | HMDB | Etoposide, alpha-D-glucopyranosyl isomer | HMDB | Ferrer brand OF etoposide | HMDB | Lemery brand OF etoposide | HMDB | Onkoworks brand OF etoposide | HMDB | Sanfer brand OF etoposide | HMDB | Vépéside sandoz | HMDB | Ribosepharm brand OF etoposide | HMDB | Baxter brand OF etoposide | HMDB | Eposide | HMDB | Eto gry | HMDB | Eto-gry | HMDB | Etoposide, (5S)-isomer | HMDB | Etoposido ferrer farma | HMDB | Gry brand OF etoposide | HMDB | Novartis brand OF etoposide | HMDB | Onkoposid | HMDB | Pharmachemie brand OF etoposide | HMDB | Riboposid | HMDB | Tedec meiji brand OF etoposide | HMDB | Etopos | HMDB | Etoposide, alpha D glucopyranosyl isomer | HMDB | Medac brand OF etoposide | HMDB | Prasfarma brand OF etoposide | HMDB | Teva brand OF etoposide | HMDB | VP 16 | HMDB | Vépéside-sandoz | HMDB | alpha-D-Glucopyranosyl isomer etoposide | HMDB | Teva, etoposide | HMDB |
| Show more...
---|
Chemical Formula | C29H32O13 |
---|
Average Molecular Weight | 588.5566 |
---|
Monoisotopic Molecular Weight | 588.18429111 |
---|
IUPAC Name | (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one |
---|
Traditional Name | (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one |
---|
CAS Registry Number | 33419-42-0 |
---|
SMILES | [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O |
---|
InChI Identifier | InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 |
---|
InChI Key | VJJPUSNTGOMMGY-MRVIYFEKSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Tetrahydroisoquinolines |
---|
Sub Class | Not Available |
---|
Direct Parent | Tetrahydroisoquinolines |
---|
Alternative Parents | |
---|
Substituents | - Tetrahydroisoquinoline
- 3-piperidinecarboxamide
- Piperidinecarboxamide
- Anisole
- Alkyl aryl ether
- Aralkylamine
- Benzenoid
- Piperidine
- Tertiary carboxylic acid amide
- Tertiary aliphatic amine
- Amino acid or derivatives
- Tertiary amine
- Carboxamide group
- Carboxylic acid ester
- Azacycle
- Carboxylic acid derivative
- Ether
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Organopnictogen compound
- Carbonyl group
- Organic nitrogen compound
- Organic oxide
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 236 - 251 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.98 g/L | Not Available | LogP | 1 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Etoposide,1TMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4537.9 | Semi standard non polar | 33892256 | Etoposide,1TMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4479.3 | Semi standard non polar | 33892256 | Etoposide,1TMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4497.7 | Semi standard non polar | 33892256 | Etoposide,2TMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4441.5 | Semi standard non polar | 33892256 | Etoposide,2TMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4462.7 | Semi standard non polar | 33892256 | Etoposide,2TMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4439.1 | Semi standard non polar | 33892256 | Etoposide,3TMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C | 4411.9 | Semi standard non polar | 33892256 | Etoposide,1TBDMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C(C)(C)C | 4735.7 | Semi standard non polar | 33892256 | Etoposide,1TBDMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4682.0 | Semi standard non polar | 33892256 | Etoposide,1TBDMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4696.6 | Semi standard non polar | 33892256 | Etoposide,2TBDMS,isomer #1 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C(C)(C)C | 4853.1 | Semi standard non polar | 33892256 | Etoposide,2TBDMS,isomer #2 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O[Si](C)(C)C(C)(C)C | 4874.3 | Semi standard non polar | 33892256 | Etoposide,2TBDMS,isomer #3 | COC1=CC([C@@H]2C3=CC4=C(C=C3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O[Si](C)(C)C(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O | 4859.1 | Semi standard non polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0bvi-1901070000-74ac7d5d623bed96366e | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (1 TMS) - 70eV, Positive | splash10-0mm1-2900107000-099107e3dc57314671ef | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS ("Etoposide,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Etoposide GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-qTof , Positive-QTOF | splash10-004r-0690000000-25202a61d19d3dfaed8b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-004r-0090420000-e5d6bcd633116e0553a0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-004i-0190000000-ac64a57347a9295be5dc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-004r-0590000000-e0e45774111103754c46 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-002r-0980000000-ccf595459b4b1988d77a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide LC-ESI-QTOF , positive-QTOF | splash10-002r-0950000000-4d3313053107615d463a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 30V, Positive-QTOF | splash10-004r-0590000000-e653736b252cc5e2e795 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 40V, Positive-QTOF | splash10-002r-0980000000-48f8ee63240c179183f6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 10V, Positive-QTOF | splash10-004r-0090420000-4257cbcff5646216f202 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-004r-0590000000-8c7420414be0c3746aff | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-002r-0091540000-94d46ba9cac17da0c456 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 40V, Positive-QTOF | splash10-000i-0930000000-d9d8244725f2e57fce96 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 35V, Negative-QTOF | splash10-0019-0397150000-e467d625bbc856208c08 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-000i-0930000000-2f7ed12e16b6771697e6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-004i-0290010000-9da8eeb575b398d3bdbd | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 6V, Positive-QTOF | splash10-000i-0930000000-d15ca68c1981073da181 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 50V, Positive-QTOF | splash10-002r-0950000000-4d3313053107615d463a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 35V, Positive-QTOF | splash10-004i-0390000000-b642957170b052134776 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Etoposide 10V, Positive-QTOF | splash10-002r-0091670000-9a34ca7c7757308b4693 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 10V, Positive-QTOF | splash10-0uei-0106690000-bd98e3ad1ce23f0413c0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 20V, Positive-QTOF | splash10-0ue9-0119510000-51cff21db98c0ed7effd | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 40V, Positive-QTOF | splash10-0ue9-0219300000-8bb469d4a7eadf8f5308 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 10V, Negative-QTOF | splash10-000j-1306090000-5791526d6f416ac328bf | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 20V, Negative-QTOF | splash10-000t-2009030000-3ed5cbe07a1ce3f87bf6 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Etoposide 40V, Negative-QTOF | splash10-000t-2009000000-41d7c2765f3c44df7f34 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00773 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00773 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00773 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 33510 |
---|
KEGG Compound ID | C01576 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Etoposide |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 36462 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 4911 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9. Epub 2007 Jun 19. [PubMed:17578914 ]
- Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES: Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer. 2001 Sep 1;85(5):747-51. [PubMed:11531262 ]
|
---|